Functional Analysis of Neutralizing Antibodies Against Clostridium Perfringens Epsilon-toxin

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2007 Jan 31

PMID 17261609

Citations 19

Authors

Mark S McClain

Timothy L Cover

Affiliations

Soon will be listed here.

Abstract

The Clostridium perfringens epsilon-toxin causes a severe, often fatal illness (enterotoxemia) characterized by cardiac, pulmonary, kidney, and brain edema. In this study, we examined the activities of two neutralizing monoclonal antibodies against the C. perfringens epsilon-toxin. Both antibodies inhibited epsilon-toxin cytotoxicity towards cultured MDCK cells and inhibited the ability of the toxin to form pores in the plasma membranes of cells, as shown by staining cells with the membrane-impermeant dye 7-aminoactinomycin D. Using an antibody competition enzyme-linked immunosorbent assay (ELISA), a peptide array, and analysis of mutant toxins, we mapped the epitope recognized by one of the neutralizing monoclonal antibodies to amino acids 134 to 145. The antibody competition ELISA and analysis of mutant toxins suggest that the second neutralizing monoclonal antibody also recognizes an epitope in close proximity to this region. The region comprised of amino acids 134 to 145 overlaps an amphipathic loop corresponding to the putative membrane insertion domain of the toxin. Identifying the epitopes recognized by these neutralizing antibodies constitutes an important first step in the development of therapeutic agents that could be used to counter the effects of the epsilon-toxin.

Citing Articles

Statins as Potential Preventative Treatment of ETX and Multiple Pore-Forming Toxin-Induced Diseases.

Huang J, Zhao B, Liu T, Kang L, Li J, Guo Z Int J Mol Sci. 2023; 24(6).

PMID: 36982489 PMC: 10048941. DOI: 10.3390/ijms24065414.

Inhibition of Pore-Forming Proteins.

Omersa N, Podobnik M, Anderluh G Toxins (Basel). 2019; 11(9).

PMID: 31546810 PMC: 6784129. DOI: 10.3390/toxins11090545.

A Novel Panel of Rabbit Monoclonal Antibodies and Their Diverse Applications Including Inhibition of Epsilon Toxin Oligomerization.

Linden J, Telesford K, Shetty S, Winokour P, Haigh S, Cahir-McFarland E Antibodies (Basel). 2019; 7(4).

PMID: 31544887 PMC: 6698963. DOI: 10.3390/antib7040037.

A small bioactive glycoside inhibits epsilon toxin and prevents cell death.

Shivappagowdar A, Pati S, Narayana C, Ayana R, Kaushik H, Sah R Dis Model Mech. 2019; 12(10).

PMID: 31492678 PMC: 6826021. DOI: 10.1242/dmm.040410.

Clostridium perfringens Epsilon Toxin Compromises the Blood-Brain Barrier in a Humanized Zebrafish Model.

Adler D, Linden J, Shetty S, Ma Y, Bokori-Brown M, Titball R iScience. 2019; 15:39-54.

PMID: 31030181 PMC: 6487375. DOI: 10.1016/j.isci.2019.04.016.

References

HUNTER S, Clarke I, Kelly D, Titball R . Cloning and nucleotide sequencing of the Clostridium perfringens epsilon-toxin gene and its expression in Escherichia coli. Infect Immun. 1992; 60(1):102-10. PMC: 257509. DOI: 10.1128/iai.60.1.102-110.1992. View

Soler-Jover A, Blasi J, Gomez de Aranda I, Navarro P, Gibert M, Popoff M . Effect of epsilon toxin-GFP on MDCK cells and renal tubules in vivo. J Histochem Cytochem. 2004; 52(7):931-42. DOI: 10.1369/jhc.4A6254.2004. View

Gubbins M, Berry J, Corbett C, Mogridge J, Yuan X, Schmidt L . Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol. 2006; 47(3):436-43. PMC: 7110350. DOI: 10.1111/j.1574-695X.2006.00114.x. View

McGuinness C, Mantis N . Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun. 2006; 74(6):3463-70. PMC: 1479246. DOI: 10.1128/IAI.00324-06. View

Keller M, Stiehm E . Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000; 13(4):602-14. PMC: 88952. DOI: 10.1128/CMR.13.4.602. View

Sidorenko G . Data on the distribution of Clostridium perfringens in the environment of man. Communication 1. J Hyg Epidemiol Microbiol Immunol. 1967; 11(2):171-7. View

BHOWN A, Habeerb A . Structural studies on epsilon-prototoxin of Clostridium perfringens type D. Localization of the site of tryptic scission necessary for activation to epsilon-toxin. Biochem Biophys Res Commun. 1977; 78(3):889-96. DOI: 10.1016/0006-291x(77)90506-x. View

Payne D, Williamson E, Havard H, Modi N, Brown J . Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett. 1994; 116(2):161-7. DOI: 10.1111/j.1574-6968.1994.tb06695.x. View

Miyamoto O, Minami J, Toyoshima T, Nakamura T, Masada T, Nagao S . Neurotoxicity of Clostridium perfringens epsilon-toxin for the rat hippocampus via the glutamatergic system. Infect Immun. 1998; 66(6):2501-8. PMC: 108230. DOI: 10.1128/IAI.66.6.2501-2508.1998. View

10.

Buxton D . Use of horseradish peroxidase to study the antagonism of Clostridium welchii (Cl. perfringens) type D epsilon toxin in mice by the formalinized epsilon prototoxin. J Comp Pathol. 1976; 86(1):67-72. DOI: 10.1016/0021-9975(76)90029-3. View

11.

Songer J . Clostridial enteric diseases of domestic animals. Clin Microbiol Rev. 1996; 9(2):216-34. PMC: 172891. DOI: 10.1128/CMR.9.2.216. View

12.

Finnie J . Histopathological changes in the brain of mice given Clostridium perfringens type D epsilon toxin. J Comp Pathol. 1984; 94(3):363-70. DOI: 10.1016/0021-9975(84)90024-0. View

13.

EBERT E, Oppling V, Werner E, Cussler K . Development and prevalidation of two different ELISA systems for the potency testing of Clostridium perfringens beta and epsilon-toxoid containing veterinary vaccines. FEMS Immunol Med Microbiol. 1999; 24(3):299-311. DOI: 10.1111/j.1574-695X.1999.tb01298.x. View

14.

Gleeson-White M, BULLEN J . Clostridium welchii epsilon toxin in the intestinal contents of man. Lancet. 1955; 268(6860):384-5. DOI: 10.1016/s0140-6736(55)91275-7. View

15.

Cole A, Gibert M, Popoff M, Moss D, Titball R, Basak A . Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol. 2004; 11(8):797-8. DOI: 10.1038/nsmb804. View

16.

Rood J . Virulence genes of Clostridium perfringens. Annu Rev Microbiol. 1999; 52:333-60. DOI: 10.1146/annurev.micro.52.1.333. View

17.

Gill D . Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982; 46(1):86-94. PMC: 373212. DOI: 10.1128/mr.46.1.86-94.1982. View

18.

Petit L, Maier E, Gibert M, Popoff M, Benz R . Clostridium perfringens epsilon toxin induces a rapid change of cell membrane permeability to ions and forms channels in artificial lipid bilayers. J Biol Chem. 2001; 276(19):15736-40. DOI: 10.1074/jbc.M010412200. View

19.

Miyata S, Minami J, Tamai E, Matsushita O, Shimamoto S, Okabe A . Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J Biol Chem. 2002; 277(42):39463-8. DOI: 10.1074/jbc.M206731200. View

20.

Miyata S, Matsushita O, Minami J, Katayama S, Shimamoto S, Okabe A . Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium perfringens epsilon-toxin in the synaptosomal membrane. J Biol Chem. 2001; 276(17):13778-83. DOI: 10.1074/jbc.M011527200. View